ESMO 2022: Updates in Sarcoma

The European Society for Medical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer. In this podcast, we hear from some of the leading experts in sarcoma, as they discuss the biggest trials and hot topics from the meeting. Tom Wei-Wu Chen (National Taiwan University Hospital, Taipei, Taiwan), discusses biomarker analyses from the LEADER (NCT03526679) trial, which investigated lenvatinib plus eribulin for patients with leiomyosarcoma and liposarcoma. Patrick Schöffski (KU Leuven, Leuven, Belgium) discusses recent advances in the management of soft tissue sarcoma (STS), and Erlinda Gordon (Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA) explains the rationale of using the combination therapy of ipilimumab plus nivolumab plus trabectedin in the first-line for patients with advanced leiomyosarcoma. Lastly, Radwa Sharaf (Foundation Medicine Inc, Cambridge, MA) provides an overview of an investigation into genomic determinant of high telomeric content beyond the canonical ATRX/DAXX alterations in sarcoma.